Podcast: A Meaningful Use Success Story
Randy Hicks, MD, and Carrie Berlin discuss how Regional Medical Imaging successfully met the criteria for the federal government’s meaningful use program, becoming an early adopter among radiology practices.
[[{"type":"media","view_mode":"media_crop","fid":"11557","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_4842072948677","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"210","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]Regional Medical Imaging, based in Flint, Mich., has successfully met the criteria for the federal government’s meaningful use program, becoming an early adopter among radiology practices. The group also received $216,000 in incentive funds so far for their efforts.
Here, Randy Hicks, MD, CEO of Regional Medical Imaging, and Carrie Berlin, chief information officer for RMI, discuss why meaningful use is important, how they implemented and attested to their use of the Merge RIS 7.0, and what other practices should consider when working toward meaningful use.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
